Transcend also saw significant improvements on secondary endpoints that assessed the rate of response, remission and loss of ...

The FDA has denied Lykos Therapeutics' marketing application for its post-traumatic stress disorder (PTSD) therapy based on MDMA, also known as ecstasy, in a setback for the emerging psychedelic ...

Multidisciplinary Association for Psychedelic Studies (MAPS), the FDA has agreed study designs for two phase 3 studies assessing MDMA-assisted psychotherapy for patients with severe PTSD.

Emory University is poised to expand its research on how MDMA, a psychedelic drug commonly known as ecstasy, could help patients with PTSD when coupled with a proven form of psychotherapy.

The fallout from the F.D.A.’s rejection of MDMA-assisted treatment for PTSD worries researchers and ... application for the first psychedelic drug to reach federal regulators was expected ...

Pictured is packaged MDMA, the main ingredient in the psychedelic drug ecstasy ... the first-ever trial of MDMA for the treatment of PTSD in active-duty soldiers. Maj. Aaron Wolfgang, a U.S ...

The Defense Department is committing two $4.9 million grants to study the effects of MDMA on post-traumatic stress disorder, one of which will enroll active-duty troops as subjects. Pictured is ...